Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth
CANTON, Mich. (2/7/2023) – MMS Holdings (MMS) – an award-winning, data-focused contract research organization (CRO) – announces the expansion of its leadership team with the appointment of Chris Schoonmaker as Chief Operating Officer. This comes as the company was recognized in the 2023 Top Workplace USA awards, a national list of organizations with strong company cultures and high employee satisfaction rates, and a Great Place to Work in India.
Schoonmaker have decades of experience in the pharmaceutical and healthcare industry and have held leadership positions at other CROs.
“We are excited to welcome Chris to the #OneMMS team,” said Dr. Uma Sharma, Chief Executive Officer, MMS. “I look forward to his leadership and strength for our continued growth as we scale our teams and clients globally to be the best in business.”
MMS Growth
The expansion of the MMS executive leadership team, will allow the company to continue growing its teams and services across its global operations.
We have strong expertise across our many services, and I look forward to connecting Sponsors with the MMS services that are the right fit for their needs.
Enhancing the MMS Mission
MMS has maintained one of the highest retention rates in the pharma industry and a positive colleague culture since its inception. These aspects of MMS enhance its mission of delivering high-quality service and technology solutions to assist clients in developing life-changing therapies.
Recently, MMS was recognized for its great company culture by the Top Workplaces USA awards for the second consecutive year. The winners of this award are chosen based solely on employee feedback gathered through an employee engagement survey.
“I’m grateful to work at a company with such a strong company culture that cares about its colleagues,” said Schoonmaker, COO, MMS. “Being a part of growing the company and developing the business strategies and operational excellence needed to continue our success is exciting and rewarding to me after many years in this space.”
MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.
Media Contact
Prasad Babu
media@mmsholdings.com
Suggested For You
news
November 7th, 2024
MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance
news
July 17th, 2024
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization
news
April 4th, 2024
MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth
news
March 6th, 2024
MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale
news
December 13th, 2023
MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD
news
April 18th, 2023
MMS Named Great Place to Work in the UK as Growth in the Region Doubles
news
March 21st, 2023
MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise
news
February 21st, 2023
MMS Partners with I-ACT to Advance Children’s Clinical Trials
news
January 11th, 2023
MMS Named a Great Place to Work in India
news
November 21st, 2022
MMS Named Michigan Top Workplace For The Second Consecutive Year
news
August 16th, 2022
Together Trial with EDC Database Designed by MMS Wins Trial of the Year
news
June 28th, 2022
MMS Holdings Partners with Lindsay Goldberg for Its Next Stage of Growth